TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23966244

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 to 16 weeks
Number of subjects: 105
Study: 23966428

Group type: EXPERIMENTAL
Intervention: 1 g Ca + 400 IU vitamin D3/d (Calcium/Vitamin D Trial)
Number of subjects: 128779

Group type: EXPERIMENTAL
Intervention: Total vitamin D intake ≥400 IU/d
Number of subjects: 128779
Study: 23966579

Group type: COMPARATOR
Intervention: TK1 activity in BRCA1/2 mutation carriers
Number of subjects: 80

Group type: COMPARATOR
Intervention: sEGFR concentration in BRCA1 mutation carriers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TK1 activity in women who developed breast cancer
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: sEGFR concentration in women who developed breast cancer
Number of subjects: 80

Group type: COMPARATOR
Intervention: sEGFR concentration in women with BSO
Number of subjects: 80
Study: 23966867

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for waist circumference (WC) adjusted for BMI
Number of subjects: 33591

Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for waist-hip ratio (WHR) adjusted for BMI
Number of subjects: 33591

Group type: COMPARATOR
Intervention: Previously reported loci for waist in European ancestry (EA) populations
Number of subjects: 33591

Group type: EXPERIMENTAL
Intervention: Association with metabolic traits
Number of subjects: 33591

Group type: EXPERIMENTAL
Intervention: Sexual dimorphism analysis
Number of subjects: 33591
Study: 23967125

Group type: EXPERIMENTAL
Intervention: 2 hours aerobic exercise (50% of VO2max)
Number of subjects: 18
Study: 23968316

Group type: EXPERIMENTAL
Intervention: Patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Patient training programme
Number of subjects: 333
Study: 23968744

Group type: EXPERIMENTAL
Intervention: Bovine milk-based preterm formula (BOV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exclusive human milk diet of pasteurized donor human milk and human milk-based human milk fortifier (HUM)
Number of subjects: 0
Study: 23969187

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.22 mg/kg/d) for 12 months
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metreleptin treatment for 12 months
Number of subjects: 5
Study: 23969281

Group type: EXPERIMENTAL
Intervention: Actions taken to relieve withdrawal symptoms (e.g., nicotine use)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms (e.g., anxiety, cannabis craving)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quitting strategies used to maintain abstinence
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-identified most helpful quitting strategy
Number of subjects: 120
Study: 23969476

Group type: EXPERIMENTAL
Intervention: Bradycardia pacemaker (PM) implantation
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Bradycardia pacemaker (PM) implantation without concomitant cardiovascular disease
Number of subjects: 1517
Study: 23969788

Group type: EXPERIMENTAL
Intervention: Surgical cytoreduction to microscopic residual
Number of subjects: 189

Group type: COMPARATOR
Intervention: Residual disease status
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low-grade serous carcinoma with measurable residual disease
Number of subjects: 189
Study: 23970149

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 158
Study: 23970502

Group type: EXPERIMENTAL
Intervention: 2010 McDonald criteria for MS diagnosis
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Inclusion of symptomatic lesions in DIT criteria
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 2010 DIS criteria
Number of subjects: 109

Group type: COMPARATOR
Intervention: 2005 DIS criteria
Number of subjects: 109
Study: 23970541

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (1 hour, three times per week for 16 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no supervised physical exercise)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 23970725

Group type: EXPERIMENTAL
Intervention: Mifepristone treatment
Number of subjects: 0
Study: 23971740

Group type: EXPERIMENTAL
Intervention: Calcitriol 0.75 mcg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcitriol + Lisinopril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo + Lisinopril
Number of subjects: 40
Study: 23972303

Group type: EXPERIMENTAL
Intervention: Average RNFL thickness < 86 μm
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Average RNFL thickness > 86 μm
Number of subjects: 287
Study: 23972346

Group type: EXPERIMENTAL
Intervention: CIED infection
Number of subjects: 64893

Group type: EXPERIMENTAL
Intervention: CIED infection in women
Number of subjects: 64893

Group type: EXPERIMENTAL
Intervention: CIED infection in women compared to men
Number of subjects: 64893

Group type: EXPERIMENTAL
Intervention: CIED infection after index admission
Number of subjects: 64893
Study: 23972788

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0
Study: 23973693

Group type: EXPERIMENTAL
Intervention: Highest HDL-C quartile
Number of subjects: 2193

Group type: EXPERIMENTAL
Intervention: Highest HDL-C quintile among subjects with LDL-C <70 mg/dl
Number of subjects: 2193

Group type: COMPARATOR
Intervention: Lowest HDL-C quartile
Number of subjects: 2193
Study: 23974909

Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computed tomography (CT)
Number of subjects: 18
Study: 23974925

Group type: EXPERIMENTAL
Intervention: Awake and fed thermogenesis (AFT)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: AFT normalized as a percentage of intake
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: AFT
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Residual variance of AFT
Number of subjects: 509
Study: 23974944

Group type: EXPERIMENTAL
Intervention: Brisk walking intervention (3 times/week for 3 months)
Number of subjects: 44
Study: 23975330

Group type: EXPERIMENTAL
Intervention: Physical activity assessed by accelerometer (counts/minute)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Physical activity assessed by 7-day PAR (MET/hour/week)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Physical activity (counts/minute)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Physical activity (MET/hour/week)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Physical activity measures
Number of subjects: 1345
Study: 23975665

Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² at week 1, then 250 mg/m²/week) and Gemcitabine (1 g/m² on day 1, 8 and 15 every 4 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cetuximab and Gemcitabine
Number of subjects: 44
Study: 23976960

Group type: EXPERIMENTAL
Intervention: Trivalent surface antigen, inactivated influenza vaccine (15 µg hemagglutinin of each virus strain)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Trivalent surface antigen, inactivated influenza vaccine
Number of subjects: 126
Study: 23977071

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) implantation in a non-hospital setting
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM) implantation
Number of subjects: 65
Study: 23978163

Group type: EXPERIMENTAL
Intervention: CBMNC transplantation and rehabilitation therapy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Combination of CBMNC and UCMSC transplantation and rehabilitation therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy only)
Number of subjects: 37
Study: 23978271

Group type: COMPARATOR
Intervention: 24 h-CASP (114 ± 17 mmHg in C, 115 ± 13 in SN, 121 ± 13 in LN, 119 ± 16 in Mi, 121 ± 13 in Ma)
Number of subjects: 715

Group type: COMPARATOR
Intervention: 24 h-CPP (38 ± 8 mmHg in C, 38 ± 7 in SN, 44 ± 10 in LN, 46 ± 11 in Mi, 46 ± 11 in Ma)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for CVD per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for CVD per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for retinopathy per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for retinopathy per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for autonomic dysfunction per 1 standard deviation increase in 24 h-CASP
Number of subjects: 715

Group type: COMPARATOR
Intervention: Odds ratios for autonomic dysfunction per 1 standard deviation increase in 24 h-CPP
Number of subjects: 715
Study: 23978364

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitors
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Newer agents (prasugrel or ticagrelor)
Number of subjects: 1434
Study: 23978572

Group type: EXPERIMENTAL
Intervention: Ovation Abdominal Stent Graft System
Number of subjects: 161
Study: 23978690

Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary application and health counseling
Number of subjects: 151

Group type: COMPARATOR
Intervention: Mobile phone with diabetes diary application without health counseling
Number of subjects: 151
Study: 23979273

Group type: EXPERIMENTAL
Intervention: mtDNA DAMP levels in patients with SIRS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: mtDNA DAMP levels in patients who developed MODS
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Above-median mtDNA DAMP levels
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Patients who died secondary to severe MODS
Number of subjects: 4
Study: 23979288

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle modification and medical therapy
Number of subjects: 40
Study: 23979353

Group type: EXPERIMENTAL
Intervention: Intensified therapy for 12 months
Number of subjects: 746
Study: 23979626

Group type: EXPERIMENTAL
Intervention: S-ICD System (Cameron Health/Boston Scientific)
Number of subjects: 330
Study: 23979733

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus Dolutegravir (DTG) 50 mg every 24 h for 5 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg every 24 h for 11 or 12 days plus GSK1265744 30 mg every 24 h for 12 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dolutegravir (DTG) 50 mg every 24 h for 5 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: GSK1265744 (30 mg every 24 h for 12 days)
Number of subjects: 27
Study: 23979787

Group type: EXPERIMENTAL
Intervention: Weight loss diet plan for 2 months
Number of subjects: 29
Study: 23980534

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 13
Study: 23980906

Group type: EXPERIMENTAL
Intervention: Betaine HCl (1500 mg orally with 90 mL of water)
Number of subjects: 6
Study: 23981504

Group type: EXPERIMENTAL
Intervention: Topical microemulsion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23981683

Group type: EXPERIMENTAL
Intervention: Rheumatologists' assessment of medical history, physical examination, and laboratory tests.
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Rheumatologists' assessment with added diagnostic laboratory tests.
Number of subjects: 949

Group type: EXPERIMENTAL
Intervention: Patients diagnosed with PsA.
Number of subjects: 949
Study: 23982845

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 μg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no ocriplasmin injection)
Number of subjects: 34
Study: 23982860

Group type: EXPERIMENTAL
Intervention: Bone morphogenetic protein 6 (BMP-6) overexpression via adeno-associated virus-mediated gene transfer in C57BL/6 mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0
Study: 23982888

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease (CKD)
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: Each standard deviation decline in estimated GFR
Number of subjects: 12866

Group type: EXPERIMENTAL
Intervention: Proteinuria and hematuria (markers of kidney damage)
Number of subjects: 12866
Study: 23982906

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 177
Study: 23983212

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 600 mg twice daily for up to 10 days
Number of subjects: 130
Study: 23983245

Group type: EXPERIMENTAL
Intervention: Multielectrode radiofrequency (MER) system with procedural changes (therapeutic vitamin K antagonist and heparin, submerged loading of the catheter, deactivation of either distal or proximal electrode)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 23983680

Group type: EXPERIMENTAL
Intervention: HP eradication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive HP strains
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OLGA staging system and tissue biomarkers integration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RPRM as circulating cell-free DNA
Number of subjects: 0
Study: 23983684

Group type: EXPERIMENTAL
Intervention: 0.7 μg/kg dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study: 23983690

Group type: EXPERIMENTAL
Intervention: 3D software planning, guided surgery, immediate loading, CAD-CAM full arch frameworks
Number of subjects: 20
Study: 23983804

Group type: EXPERIMENTAL
Intervention: Intense multipurpose exercise program (EG)
Number of subjects: 137
Study: 23983807

Group type: EXPERIMENTAL
Intervention: TZD + EA (Electroacupuncture)
Number of subjects: 31

Group type: COMPARATOR
Intervention: TZD (Control)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TZD + EA
Number of subjects: 31

Group type: COMPARATOR
Intervention: TZD
Number of subjects: 31
Study: 23983823

Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus STn-KLH vaccine
Number of subjects: 1028

Group type: COMPARATOR
Intervention: KLH alone
Number of subjects: 1028

Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus STn-KLH vaccine with median or greater antibody response
Number of subjects: 1028
Study: 23983980

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 178

Group type: COMPARATOR
Intervention: Quetiapine IR
Number of subjects: 178
Study: 23984046

Group type: EXPERIMENTAL
Intervention: Leucine + phenylalanine (1 mmol/kg fat free body mass each) + 25 g glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Leucine (1 mmol/kg fat free body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenylalanine (1 mmol/kg fat free body mass)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 8
Study: 23984050

Group type: EXPERIMENTAL
Intervention: VBLOC device (Maestro Rechargeable System)
Number of subjects: 28
Study: 23984053

Group type: EXPERIMENTAL
Intervention: Nutritional and physical activity intervention (DVD and clinician toolkit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 23984082

Group type: EXPERIMENTAL
Intervention: 2.5 mg mifepristone daily for 3 months
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: 5 mg mifepristone daily for 3 months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 220
Study: 23984185

Group type: EXPERIMENTAL
Intervention: 250 μCi of (131)I/mL thyroid tissue, corrected by 24-RAIU values (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 200 μCi of (131)I/mL/24-RAIU (Group 2, historical control)
Number of subjects: 30
Study: 23984729

Group type: COMPARATOR
Intervention: ALN-TTR01 (1.0 mg/kg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: ALN-TTR02 (0.15 to 0.3 mg/kg)
Number of subjects: 49
Study: 23984897

Group type: EXPERIMENTAL
Intervention: Various treatment options for ductal carcinoma in situ, specific interventions not detailed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical clearance and radiation therapies, specific details not provided.
Number of subjects: 0
Study: 23985703

Group type: EXPERIMENTAL
Intervention: Benidipine combined with β-blocker (BB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benidipine combined with thiazide diuretic (TD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benidipine combined with angiotensin receptor blocker (ARB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benidipine-BB regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benidipine-TD regimen
Number of subjects: 0
Study: 23985804

Group type: EXPERIMENTAL
Intervention: 8-wk very-low-energy diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Weight maintenance after diet
Number of subjects: 51
Study: 23985807

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (nonoverweight adolescents)
Number of subjects: 29
Study: 23986161

Group type: EXPERIMENTAL
Intervention: Calcipotriene plus betamethasone dipropionate topical suspension
Number of subjects: 43
Study: 23986162

Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg BID for 12 weeks
Number of subjects: 30
Study: 23986513

Group type: EXPERIMENTAL
Intervention: CCX140-B treatment in diet-induced obese mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCX140-B treatment in both models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CCX140-B
Number of subjects: 0
Study: 23987834

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Activin A (actA)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional CV risk factors
Number of subjects: 135
Study: 23988361

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT) with alteplase for 1-4 days
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard treatment with 6 months of anticoagulation and 24 months of compression stockings
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Patients with post-thrombotic syndrome (PTS)
Number of subjects: 189
Study: 23988636

Group type: EXPERIMENTAL
Intervention: Needle insertion into fresh porcine shoulder tissue
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Needle insertion into in vivo human tissues
Number of subjects: 82
Study: 23989115

Group type: EXPERIMENTAL
Intervention: CPR training intention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Performing CPR intention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Attitudinal beliefs
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Factors influencing CPR training intention
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Factors influencing CPR performance intention
Number of subjects: 412
Study: 23989301

Group type: EXPERIMENTAL
Intervention: Left atrial catheter ablation
Number of subjects: 37
Study: 23989950

Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg daily continuously with a 28-day cycle)
Number of subjects: 37
Study: 23990665

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 15
Study: 23990869

Group type: EXPERIMENTAL
Intervention: Genomic Grade Index (GGI)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: MapQuant test
Number of subjects: 180

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 180
Study: 23991111

Group type: EXPERIMENTAL
Intervention: Interleukin 1 receptor antagonist (IL-1RA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pro-inflammatory mediators (CRP, IL-6, MCP-4)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Immune mediator network (IL-1RA, CRP, IL-6, MCP-4, MIP-1ß)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: IL-1RA
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Th1-associated mediators (IFNγ and IP-10)
Number of subjects: 89
Study: 23993427

Group type: EXPERIMENTAL
Intervention: TCN-PM (triciribine phosphate monohydrate)
Number of subjects: 0
Study: 23993936

Group type: EXPERIMENTAL
Intervention: Bicarbonate values
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Absence of a primary care provider
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ondansetron administration
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Volume of intravenous fluids administered
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Baseline clinical dehydration score
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate values
Number of subjects: 174
Study: 23994535

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 41

Group type: COMPARATOR
Intervention: CT
Number of subjects: 41
Study: 23994660

Group type: EXPERIMENTAL
Intervention: Sertraline 50mg to 200mg/day
Number of subjects: 31
Study: 23996087

Group type: EXPERIMENTAL
Intervention: dmPGE2-treated UCB units
Number of subjects: 12
Study: 23996484

Group type: EXPERIMENTAL
Intervention: Tipifarnib
Number of subjects: 0
Study: 23996499

Group type: EXPERIMENTAL
Intervention: Arteriograph
Number of subjects: 22

Group type: COMPARATOR
Intervention: Invasive measurement
Number of subjects: 22
Study: 23996605

Group type: EXPERIMENTAL
Intervention: Water quality intervention
Number of subjects: 13760

Group type: EXPERIMENTAL
Intervention: Sanitation intervention
Number of subjects: 13760

Group type: EXPERIMENTAL
Intervention: Handwashing intervention
Number of subjects: 13760

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 13760

Group type: EXPERIMENTAL
Intervention: Combined water+sanitation+handwashing (WSH) intervention
Number of subjects: 13760

Group type: EXPERIMENTAL
Intervention: Combined WSH+nutrition intervention
Number of subjects: 13760

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13760
Study: 23996808

Group type: EXPERIMENTAL
Intervention: Skeletal muscle mass index (SMI)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Liver attenuation index (LAI)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Lowest quartile of SMI
Number of subjects: 452
Study: 23997960

Group type: EXPERIMENTAL
Intervention: Physical exercise with a stationary bicycle once a week for 30 minutes, under professional supervision.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group not engaged in any physical exercise.
Number of subjects: 116